Eli Lilly and Company $LLY Stock Acquired by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 1.2% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 236,643 shares of the company’s stock after acquiring an additional 2,700 shares during the quarter. Eli Lilly and Company accounts for about 2.0% of Mn Services Vermogensbeheer B.V.’s investment portfolio, making the stock its 10th largest position. Mn Services Vermogensbeheer B.V.’s holdings in Eli Lilly and Company were worth $273,815,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Integrity Financial Corp WA grew its holdings in shares of Eli Lilly and Company by 1.3% during the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock worth $767,000 after purchasing an additional 8 shares in the last quarter. Willner & Heller LLC raised its stake in Eli Lilly and Company by 1.0% in the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock valued at $1,100,000 after purchasing an additional 9 shares in the last quarter. Aspiring Ventures LLC raised its stake in Eli Lilly and Company by 3.7% in the second quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock valued at $306,000 after purchasing an additional 9 shares in the last quarter. Wealthspan Partners LLC lifted its position in Eli Lilly and Company by 0.4% during the second quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock valued at $2,543,000 after purchasing an additional 9 shares during the last quarter. Finally, Navigoe LLC grew its stake in Eli Lilly and Company by 8.7% in the 2nd quarter. Navigoe LLC now owns 113 shares of the company’s stock worth $135,000 after buying an additional 9 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on Eli Lilly (LLY) to $1,440 from $1,410 and maintained an “overweight” rating, implying substantial upside from recent trading levels. Cantor Fitzgerald price target report
• Positive Sentiment: Lilly and Nvidia committed up to $1 billion to establish an artificial-intelligence drug-discovery laboratory. The initiative could improve research efficiency and strengthen Lilly’s future pipeline, although financial benefits are likely long term. Nvidia and Eli Lilly AI drug discovery lab
• Positive Sentiment: Investor commentary remains bullish on Lilly’s growth beyond Mounjaro and Zepbound, highlighting retatrutide, manufacturing expansion, oncology products and other pipeline opportunities. Retatrutide’s potential for greater weight loss could provide another major growth driver if late-stage trials and regulatory review succeed. Eli Lilly obesity business analysis
• Positive Sentiment: New early-stage studies are expanding Lilly’s obesity and Alzheimer’s pipelines, while its oncology portfolio—including Jaypirca, Inluriyo and Retevmo—could offset slower growth from mature products. Lilly obesity drug trial
• Neutral Sentiment: Lilly signed a research collaboration and licensing agreement with InnoCare Pharma covering as many as five drug targets. The deal broadens potential discovery opportunities, but the targets remain early-stage and do not yet provide near-term revenue visibility. InnoCare and Eli Lilly deal
• Negative Sentiment: LLY remains valued at roughly 40 times trailing earnings, leaving the shares sensitive to slowing growth, pricing pressure and stronger competition in the GLP-1 market. Recent commentary argues the long-term opportunity is attractive but acknowledges that expectations are already high.
• Negative Sentiment: New WHO childhood-obesity guidance may increase scrutiny around the use, access and long-term safety of obesity medicines, creating regulatory and reimbursement uncertainty for Lilly and Novo Nordisk. WHO childhood obesity guidelines

Insider Activity

In other news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 23rd. Guggenheim lifted their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. Bank of America upped their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Cantor Fitzgerald increased their target price on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, The Goldman Sachs Group lifted their price target on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a research note on Thursday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,169.77 on Friday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 52-week low of $783.85 and a 52-week high of $1,292.65. The company has a fifty day moving average of $1,173.78 and a 200-day moving average of $1,096.45. The stock has a market capitalization of $1.10 trillion, a price-to-earnings ratio of 39.25, a price-to-earnings-growth ratio of 1.46 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm’s revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the company earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts expect that Eli Lilly and Company will post 36.66 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.